Lower observed versus expected (based on U.S. age and gender specific rates) survival in patients treated for near-fatal ventricular arrhythmias.
Lower observed versus expected (based on U.S. age and gender specific rates) survival in patients treated for near-fatal ventricular arrhythmias.
复制标题
接受近乎致命的室性心律失常治疗的患者的观察到的生存率低于预期（基于美国年龄和性别特定比率）。
DOI：
10.1111/j.1540-8159.2004.00416.x
复制
发表时间：
2004
期刊：
影响因子：
--
通讯作者：
AVIDInvestigators
中科院分区：
文献类型：
--
作者：
Kulasingam,ShaliniL;Akiyama,Toshio;Mounsey,JPaul;Ledingham,Robert;Hallstrom,AlfredP;AVIDInvestigators
植入式心律转复除颤器（ICD）可改善室颤（VF）或持续性室性心动过速（VT）患者的生存率。然而，与一般人群相比，这些患者的生存率尚未评估。随机接受任一抗肿瘤药物治疗的患者的观察生存率（主要是胺碘酮）组或ICD组与预期率进行比较，使用1989-1991年美国人口生命表得出的年龄和性别特异性生存率计算，并应用于每组患者的年龄和性别分布。与抗心律失常药与植入式除颤器（AVID）试验的结果一致，随机接受ICD治疗的患者的生存率显著高于药物治疗组;然而，两组的生存率均显著低于使用年龄和性别匹配的美国生存率的预期。组内，ICD组3年随访期间观察到的发生率与预期发生率之间的差异从7.7%增加至15.3%，从14.6%上升到26.4%这些结果量化了使用药物或ICD治疗的VF或VT患者预期的生存率改善，并强调需要继续研究进一步改善治疗的方法。这些患者的整体健康水平。(PACE 2004; 27：230-234）
Implantable cardioverter defibrillators (ICDs) have improved survival for patients with ventricular fibrillation (VF) or sustained vertricular tachycardia (VT). However, the survival of these patients compared to the general population has not been assessed. Observed survival rates for patients randomized to either antiarrhythmic drug therapy (mainly amiodarone) arm or ICD arm were compared to expected rates, calculated using age and sex‐specific survival rates derived from the 1989–1991 US population life tables and applied to the age and sex distribution of patients in each arm. Consistent with the results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial, patients randomized to receive ICDs experienced significantly higher survival than those in the drug arm; however, both groups experienced significantly lower survival than expected using age and gender matched U.S. survival rates. Within arms, the difference between the observed and expected rates increased over 3 years of follow‐up from 7.7% to 15.3% for the ICD arm, and from 14.6% to 26.4% for the drug arm. These results quantify the improvements in survival that can be expected for VF or VT patients using drug or ICD therapies and underscore the need for continued research into methods for further improving the overall level of health of these patients. (PACE 2004; 27: 230–234)